Skip to Content

Rule

Dosage Form New Animal Drugs; Change of Sponsor; Technical Amendment

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for four approved new animal drug applications (NADAs) from Anthony Products, Co. to Cross Vetpharm Group, Ltd.

DATES:

This rule is effective June 20, 2003.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail: dnewkirk@cvm.fda.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Anthony Products, Co., 5600 Peck Rd., Arcadia, CA 91006, has informed FDA that it has transferred ownership of, and all rights and interest in, the following four approved NADAs to Cross Vetpharm Group, Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland.

NADA NumberTrade Name21 CFR Section
049-187PHEN-BUTA (phenylbutazone) Vet Tablets; Phenylbutazone Tablets (Dogs)520.1720a
122-447FURA-SEPTIN (nitrofurazone) Soluble Dressing524.1580b
130-136Oxytocin Injection522.1680
140-582BIOCYL 50; BIOCYL 100 (oxytetracycline)522.1662a

Accordingly, the agency is amending the regulations in §§ 522.1662a, 522.1680, and 524.1580b (21 CFR 522.1662a, 522.1680, and 524.1580b) to reflect the transfer of ownership. No amendment of 21 CFR 520.1720a is necessary as each sponsor owns additional phenylbutazone products.

In addition, § 522.1662a is being revised to reflect current format. This action is being taken to improve consistency between sections of the regulations.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because Start Printed Page 36913it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects in 21 CFR Parts 522 and 524

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

2. Section 522.1662a

End Amendment Part Start Amendment Part

3. Section 522.1680 is amended in paragraph (b) by removing “000864” and by numerically adding “061623”; in paragraph (c) by removing the footnote; in paragraphs (c)(1)(i) and (c)(1)(ii) in the table headings by removing “ml” and by adding in its place “mL”; and by revising paragraphs (a) and (c)(3) to read as follows:

End Amendment Part
Oxytocin injection.

(a) Specifications. Each milliliter (mL) of solution contains 20 USP units oxytocin.

* * * * *

(c) * * *

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Start Part

PART 524-OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

4. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

5. Section 524.1580b

End Amendment Part Start Signature

Dated: June 3, 2003.

Steven D. Vaughn,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 03-15618 Filed 6-19-03; 8:45 am]

BILLING CODE 4160-01-S